LU-CHENG KUOLai C.-C.Liao C.-H.Hsu C.-K.Chang Y.-L.Chang C.-Y.PO-REN HSUEH2020-12-232020-12-2320071198-743Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-33846332693&doi=10.1111%2fj.1469-0691.2006.01601.x&partnerID=40&md5=0714c94fdb5a130c4cee7a68c0c32194https://scholars.lib.ntu.edu.tw/handle/123456789/530814Nosocomial infections caused by Acinetobacter baumannii have increased in recent years. Isolates of multidrug-resistant A.baumannii (MDRAB) have been recovered in Taiwan since 1999. The characteristics of 55 patients with MDRAB bacteraemia infections occurring between January 2003 and February 2005 were analysed retrospectively. The overall 30-day mortality rate was 49%. The portal of entry was identified in 80% of patients, with the respiratory tract being implicated most frequently. Among the different antimicrobial regimens prescribed, the combination of a carbapenem and ampicillin-sulbactam was associated with a better outcome than the combination of a carbapenem and amikacin, or a carbapenem alone. ? 2007 European Society of Clinical Microbiology and Infectious Diseases.[SDGs]SDG3amikacin; antibiotic agent; aztreonam; carbapenem; cefepime; ceftazidime; cephalosporin derivative; ciprofloxacin; colistin; doxycycline; gentamicin; imipenem; meropenem; ofloxacin; piperacillin plus tazobactam; quinoline derived antiinfective agent; rifampicin; sultamicillin; tigecycline; timentin; Acinetobacter baumannii; adolescent; adult; aged; antibiotic resistance; antibiotic sensitivity; article; bacteremia; catheter infection; central nervous system infection; child; clinical feature; combination chemotherapy; controlled study; drug response; drug treatment failure; female; human; infant; major clinical study; male; monotherapy; mortality; multidrug resistance; prescription; priority journal; respiratory tract infection; retrospective study; treatment outcome; urinary tract infection; wound infection; Acinetobacter baumanniijournal article10.1111/j.1469-0691.2006.01601.x173287332-s2.0-33846332693